Search Results

Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024

Beactica Therapeutics AB announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024.

February 14, 2024

·

2 min read

Drug Development

Beactica Therapeutics strengthens its preclinical development team

Beactica Therapeutics AB, the Swedish precision oncology company, announced two appointments to its preclinical development team.

September 12, 2023

·

3 min read

Business

Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences

Beactica Therapeutics AB, the Swedish precision oncology company, announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences, one of 27 institutes and centers at the U.S. National Institutes of Health.

September 26, 2023

·

2 min read

Drug Development

Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate

Beactica Therapeutics AB announced the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers.

September 5, 2023

·

2 min read

Business

Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities

Beactica Therapeutics AB, the Swedish precision oncology company, announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors.

June 19, 2023

·

2 min read

Business

Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration

Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc., the Korean drug development company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.

April 4, 2023

·

2 min read

Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023

Beactica Therapeutics AB, the Swedish precision oncology company, announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.

May 16, 2023

·

2 min read

Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

Beactica Therapeutics AB, the Swedish precision oncology company, announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research’s Annual Meeting 2023.

April 11, 2023

·

2 min read

Policy

Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma

Beactica Therapeutics AB announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma.

February 1, 2023

·

2 min read

Business

Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration

Dong-A ST Co., Ltd., a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.

September 6, 2022

·

3 min read